9887 (9887) News
Follow 9887 (9887) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
FDA Grants Fast Track Designation to Nanjing Leads Biolabs’ Opamtistomig
The designation covers first-line advanced or metastatic biliary tract cancer. It is the program’s second Fast Track, and the FDA urged prompt talks on U.S. registration plans for the chemotherapy combination.
REGULATION | Oct 12, 2026, 01:51 AM UTC
L
Nanjing Leads Biolabs Co., Ltd. Wins Japan Orphan Drug Status for LBL-024
Nanjing Leads Biolabs said Japan’s MHLW granted Orphan Drug Designation to opamtistomig (LBL-024) for extrapulmonary neuroendocrine carcinoma, adding to prior U.S. and EU ODDs. The company notes potential development and
NEWS | Sep 28, 2026, 06:51 AM UTC
L
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
NANJING, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that opamtistomig (LBL-024), the Company’s proprietary PD—L1/4—1B
GEOPOLITICS | Sep 28, 2026, 06:51 AM UTC